Journal
FUTURE MEDICINAL CHEMISTRY
Volume 11, Issue 2, Pages 119-135Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc-2018-0248
Keywords
cancer; chemoresistance; chemotherapy; cisplatin; metal-based anticancer agents
Categories
Funding
- Avner Pancreatic Cancer Foundation
- Keith & Ann Vaughan Fund
Ask authors/readers for more resources
Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available